Int'l. App. No.: PCT/GB00/ Int'l. Filing Date: 29 September 2000

- 15. A method of determining the phenotypic effect of a compound, said method comprising the steps of:
  - (1) exposing a transgenic rodent claim 1 to said compound;
  - (2) and determining changes in phenotype.
- 16. The method according to claim 15, wherein the phenotype corresponds to a UCP3-related disease selected from the group consisting of: obesity, diabetes, hyperlipidaemia, body weight disorders, wound healing, cachexia, inflammation, tissue repair, and atherosclerosis.

#### **REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/GB00/03747 into the U.S. National Phase of prosecution. Claims 2-6, 9-12, and 14-16 have been amended to eliminate multiple dependencies and to comply with proper U.S. claim format. Furthermore, attached hereto is a marked-up version of the changes made to the application by the current preliminary amendment. The attached page is captioned, "Version with markings to show changes made."

Respectfully submitted,

Thisbook (). Hercht

Elizabeth J. Hecht Attorney for Applicants Registration No. 41,824

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5009
Facsimile (610) 270-5090



Int'l. App. No.: PCT/GB00 7
Int'l. Filing Date: 29 September 2000

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

## In the specification:

# CROSS REFERENCES TO RELATED APPLICATIONS

This newly added paragraph to the specification is solely to incorporate continuing application data. No changes have been made. Therefore, a marked up version is not required.

The newly added page to the specification is solely to incorporate the Abstract page. No changes have been made, therefore, a marked up version is not required.

#### In the claims:

- 2. [A] <u>The transgenic rodent according to claim 1 wherein the polynucleotide</u> encoding a human UCP3 polypeptide is selected from the group consisting of:
- (a) a polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the polynucleotide of SEQ ID NO:1;
- (c) a polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of SEQ ID NO:1;
- (d) the polynucleotide of SEQ ID NO:1;
- (e) a polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (f) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2;
- (g) a polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (h) a polynucleotide encoding the polypeptide of SEQ ID NO:2;

Int'l. App. No.: PCT/GB00/ Int'l. Filing Date: 29 September 2000

(i) a polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of SEQ ID NO:1; and

- (j) a polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2.
- 3. [A] <u>The</u> transgenic rodent according to claim 1 [or 2] wherein the rodent is selected from the group consisting of:
  - a) mouse; and
  - b) rat.
- 4. [A] The transgenic rodent according to [any one of] claim[s] 1 [to 3] wherein the polynucleotide encodes a human UCP3 polypeptide of SEQ ID NO:2.
- 5. [A] <u>The transgenic rodent according to [any one of] claim[s 1 to 4] 2</u> wherein the polynucleotide encoding a human UCP3 polypeptide is the polynucleotide of SEQ ID NO:1.
- 6. The transgenic rodent of [any one of] claim[s]1 [to 5] wherein the human UCP3 polypeptide is expressed predominantly in skeletal muscle.
- 9. The transgenic rodent of [any one of] claim[s]1, wherein said transgenic rodent [to 8] exhibits[ing] reduced body weight.
- 10. The transgenic rodent of [any one of] claim[s]1, wherein said transgenic rodent [to 8] exhibits[ing] increased wound-healing.
- 11. A method of producing the transgenic rodent [of any one of the preceding] <u>as</u> claimed in claim[s] <u>1, said method</u> comprising the steps <u>of</u>:

Int'l. App. No.: PCT/GB00/ Int'l. Filing Date: 29 September 2000

- a) preparing transgene construct comprising coding region of the gene of interest operably linked to an appropriate regulatory sequence;
- b) removing vector sequences by restriction digest;
- c) introducing the transgene into the rodent by pronuclear injection; and
- d) re-transferring the injected eggs into the uteri of pseudo-pregnant recipient mothers.
- 12. The [A] method of producing the [a] transgenic rodent according to claim 11, wherein the rodent is a mouse and the transgene is introduced into mouse ES cells[,] using a method selected from the group consisting of: electroporation, retroviral vectors, [or] and lipofection for gene transfer.
- 14. [A] <u>The</u> transgene according to claim 13, wherein the rodent regulatory sequence is the alpha-actin promoter.
- 15. A method of determining the phenotypic effect of a compound, said method comprising the steps of:
  - (1) exposing a transgenic rodent [of any one of] claim[s] 1 [to 10] to said compound; (2) and determining changes in phenotype.
- 16. [A] The method according to claim 15, wherein the phenotype [is that of] corresponds to a UCP3-related disease selected from the group consisting of: obesity, diabetes, hyperlipidaemia, body weight disorders, wound healing, cachexia, inflammation, tissue repair, and atherosclerosis.